The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Nab-Paclitaxel Wins Neoadjuvant Taxane Battle in Breast Cancer Trial
December 11th 2014Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.
Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels
December 10th 2014Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.
Brentuximab Vedotin Combination Shows Promise in Hodgkin Lymphoma
Ninety-six percent of patients with relapsed or refractory Hodgkin lymphoma who received treatment with the combination of brentuximab vedotin and bendamustine responded to treatment without experiencing dose-limiting toxicity.
Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL
December 9th 2014Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL
December 8th 2014Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial
December 7th 2014Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.
Frontline Idelalisib Monotherapy Yields High Response Rates in Older Patients With CLL, SLL
Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.
Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AML
December 7th 2014Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.
Carfilzomib Combination Significantly Increases PFS in Relapsed Multiple Myeloma
Treatment with carfilzomib in combination with lenalidomide and dexamethasone increased PFS by 8.7 months in patients with relapsed multiple myeloma when compared with lenalidomide and dexamethasone alone.
Dr. Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial
December 6th 2014A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.
ASH 2014 Preview: Checkpoint Inhibition, CAR Modified T Cells, and Novel Therapies
The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.